Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser
- PMID: 2245493
- DOI: 10.1007/BF00689277
Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser
Abstract
A total of 25 patients with inoperable cervical cancer were treated by daily radiotherapy (2 Gy); sensitisation was obtained by administration of 5 mg cisplatin 30 min before each irradiation session. The total cumulative dose of cisplatin varied between 50 and 150 mg. A complete kinetic profile (0-24 h) of platinum (Pt) was established after the first dose and at the end of treatment for 22 patients. Pt was quantified by atomic absorption spectrophotometry using Zeeman-effect background correction for trace analysis. The total Pt AUC0-24h increased from 1.53 +/- 0.77 to 7 +/- 3.55 micrograms.h.ml-1 between the start and the end of treatment (P less than 0.001). Ultrafilterable Pt (Pt UF) rose from 0.079 +/- 0.038 to 0.138 +/- 0.095 microgram.h.ml-1 (P less than 0.01). Elimination half-lives were unchanged for total Pt but rose for Pt UF; these kinetic modifications in Pt UF did not correlate with any significant change in individual serum creatinine levels. No clear correlation was found between the cumulative cisplatin dose and tumor levels measured in 13 patients, and the tumor cisplatin dose did not correlate with response to treatment. Patients with hematological toxicity were characterised by an increase in their residual Pt UF level during treatment. Overall, our findings strengthen the notion of Pt UF kinetic variability during repeated treatment.
Similar articles
-
Tumoral platinum concentrations in patients treated with repeated low-dose cisplatin as a radiosensitizer.Int J Cancer. 1996 Nov 15;68(4):452-6. doi: 10.1002/(SICI)1097-0215(19961115)68:4<452::AID-IJC9>3.0.CO;2-#. Int J Cancer. 1996. PMID: 8945615
-
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.Cancer Chemother Pharmacol. 2002 Mar;49(3):201-10. doi: 10.1007/s002800100371. Epub 2002 Jan 22. Cancer Chemother Pharmacol. 2002. PMID: 11935212 Clinical Trial.
-
Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia.Anticancer Res. 2003 Mar-Apr;23(2B):1509-16. Anticancer Res. 2003. PMID: 12820417
-
Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors.Ther Drug Monit. 1995 Feb;17(1):25-32. doi: 10.1097/00007691-199502000-00005. Ther Drug Monit. 1995. PMID: 7725373 Clinical Trial.
-
Clinical pharmacokinetics of carboplatin.Clin Pharmacokinet. 1991 Oct;21(4):242-61. doi: 10.2165/00003088-199121040-00002. Clin Pharmacokinet. 1991. PMID: 1760899 Review.
Cited by
-
Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients.Front Pharmacol. 2020 Jun 26;11:975. doi: 10.3389/fphar.2020.00975. eCollection 2020. Front Pharmacol. 2020. PMID: 32670072 Free PMC article.
-
Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma.Int J Clin Oncol. 2005 Dec;10(6):418-24. doi: 10.1007/s10147-005-0525-6. Int J Clin Oncol. 2005. PMID: 16369746 Clinical Trial.
-
Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).Cancer Sci. 2015 Apr;106(4):407-12. doi: 10.1111/cas.12622. Epub 2015 Mar 9. Cancer Sci. 2015. PMID: 25640628 Free PMC article. Clinical Trial.